Tissue Testing Technologies LLC

Tissue Testing Technologies LLC, based in North Charleston, US, specializes in high-quality cell and tissue preservation solutions, ensuring the viability of biological materials for research applications. Tissue Testing Technologies LLC (T3LLC) provides advanced preservation solutions for biological materials. The company operates from its headquarters in North Charleston, US. It was recently involved in a deal where LifeNet Health, Inc.

, a portfolio company of EXOR, acquired T3LLC on December 15, 2025. Details about the founder are not currently available. Tissue Testing Technologies LLC (T3LLC) specializes in high-quality cell and tissue preservation solutions for research applications, specifically designed to maintain the viability and functionality of biological materials. Their core product offerings include the Unisol™ solution, exclusively distributed in partnership with Organ Recovery Systems, as well as their proprietary Tissue Storage Solutions OSS-1 and OSS-2.

OSS-1 is recognized as a leading "gold standard" tissue preservation solution and is available in convenient small volumes to facilitate ease of use for clients, while OSS-2 is based on the EuroCollins Solution, enhancing compatibility with vitrification formulations. The company primarily serves academic and commercial organizations engaged in biological research, focusing on the preservation of human tissues and cells, ensuring they meet the necessary quality standards for effective research applications. T3LLC's products cater to a global market, offering solutions that can be customized to meet diverse research needs across various regions. Tissue Testing Technologies LLC operates on a business-to-business (B2B) model, providing its preservation solutions and contract research services to a clientele that includes academic institutions and commercial enterprises.

The revenue structure is primarily derived from direct transactions involving the sale of their preservation solutions, including the proprietary Unisol™ and the OSS-1 and OSS-2 formulations. Clients typically engage in purchasing these products in specific quantities as required for their research purposes. The company may also establish partnerships for contract research services, which involve tailored projects focusing on the procurement, transport, preservation, and storage of biological materials. The exact pricing structure for these products and services is determined based on client needs and project specifications, reinforcing T3LLC's commitment to delivering high-quality solutions aligned with the unique requirements of their customers.

The acquisition by LifeNet Health, Inc. is expected to enhance their services and capabilities going forward. While specific details regarding new product launches are not currently available, the acquisition indicates a strategic move towards expanding their market presence and product offerings. T3LLC's management will likely focus on leveraging LifeNet Health's resources to explore opportunities in new geographic regions, potentially targeting additional markets by 2026.